Altor BioScience

Altor BioScience is a privately owned clinical-stage biopharmaceutical company focused on treatment of cancers and viral infections using cytokine-based fusion proteins. As of 2017 it had raised around $27.8M from investors and around $20M in SBIR grants, and had twelve clinical trials underway. The company was spun out from Sunol in 2002 based on T cell receptor work; Sunol was previously spun out from Baxter in 1996 with the T cell receptor technology and some antibodies.

One of its products is ALT-801, which is a fusion protein of IL-2 and a soluble T-cell receptor for p53 tumor-associated antigen (p53 TCR); ALT-801 itself attacks tumors and draws an immune response against the tumor.

ALT-802 is a fusion protein combining immunoglobulin G and p53 TCR, and ALT-803 is a fusion protein of IL-15 and the sushi domain of its alpha receptor, which is directly linked to the Fc region of IgG1. ALT-803 was given fast track status by the FDA in 2017 and at that time, Phase III trials in bladder cancer were being prepared. ALT-836 (formerly called Sunol-cH36) is a human/mouse chimeric monoclonal antibody that blocks the site on tissue factor where factor X and factor IX bind to it, and was in clinical trials to treat acute lung injury and acute respiratory distress syndrome; it was originally developed at Sunol, which licensed it to Genentech, and Altor licensed it in turn.

Patrick Soon-Shiong acquired a majority stake in Altor between 2015 and 2017, and in 2017 he attempted to have another of his companies, NantCell, acquire Altor; other shareholders objected to the terms and attempted to block the deal. In October 2016 Altor and NantKwest, another Soon-Shiong company, had agreed to explore clinical trials combining each of ALT-801 and ALT-803 with NantKwest's cell therapies against cancer.

...
Wikipedia